Data on demographics, clinical features, therapy administered and treatment outcomes from 61 HER2-positive BC patients treated with neoadjuvant trastuzumab-based therapy in three Italian Cancer Centers were retrieved from our prospectively maintained database and are illustrated in Table 1. Here, ERBB2 is linked to cancer.